Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls
Authors:
- Solveig HahneSHSolveig Hahne
- Christer NordstedtCNChrister Nordstedt
- Arne ÅhlinAÅArne Åhlin
- Henrik NybäckHNHenrik Nybäck
- 1 March 1997
- journal article
- Published by Elsevier in Neuroscience Letters
- Vol. 224 (2) , 99-102
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's diseaseNeuroscience Letters, 1996
- Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brainNeuron, 1995
- Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's diseaseHuman Genetics, 1995
- Cerebrospinal fluid apolipoprotein E is reduced in Alzheimerʼs diseaseNeuroReport, 1994
- Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filamentsNature, 1994
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993
- Anti‐inflammatory agents as a therapeutic approach to Alzheimer's diseaseNeurology, 1992
- Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluidClinica Chimica Acta, 1991
- Neuropsychological test performance and CSF levels of monoamine metabolites in healthy volunteers and patients with Alzheimer's dementiaActa Psychiatrica Scandinavica, 1987
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984